We previously showed that a quantitative fecal immunochemical test (FIT) can predict mucosal healing (MH) in ulcerative colitis (UC). Fecal calprotectin (Fcal) has also been reported as an important biomarker of UC activity. The aim of this study was to compare the predictive ability of these two fecal markers for MH in UC.
INTRODUCTION
Ulcerative colitis (UC) is an infl ammatory bowel disease that causes diff use infl ammatory mucosal injury, including erosions and ulcers in the colon and rectum. Patients suff er from uncomfortable symptoms such as diarrhea, rectal bleeding, and abdominal pain, unless appropriate treatment is provided. Although immunological disorders have been shown to be involved in the occurrence of UC, its cause remains largely unknown and a complete cure is rare with the medical resources that are currently available. Th erefore, the treatment strategy for UC consists of remission induction therapy in the active stage, followed by maintenance of remission aft er successful remission induction.
In the past, UC patients were treated to achieve and sustain clinical remission, as indicated by the disappearance of clinical symptoms. Recently, however, not only clinical remission but also endoscopic (MH) is being pursued as the treatment goal for UC. Patients with UC who achieve MH have been shown to have a lower rate of relapse and a reduced risk of hospitalization and colectomy (1) (2) (3) . Although evaluation of MH absolutely requires colonoscopic observation, colonoscopy is an invasive and costly procedure, and cannot be performed frequently. Th erefore, noninvasive methods to evaluate mucosal status without performing colonoscopy are desirable. Among promising candidates that might refl ect mucosal status, surrogate markers present in stool samples have been evaluated (4) (5) (6) (7) (8) (9) (10) (11) (12) . Fecal calprotectin (Fcal), a major protein found in the cytosol of infl ammatory cells, is the most widely used marker of mucosal infl ammation. Initially, Fcal was used to predict the presence of infl ammation in infl ammatory bowel disease patients without performing colonoscopy, and was shown to predict the presence of active infl ammation in UC patients with sensitivity ranging from 71 to 93% and specifi city ranging from 71 to 100% ( 5-7 ). Subsequently, the ability of this marker to predict MH was evaluated. Although fewer studies have demonstrated the predictability of Fcal for MH than for the presence of active infl ammation in UC patients, its sensitivity for MH reportedly ranges from 65 to 100%, and its specifi city from 53 to 90% (8) (9) (10) (11) .
Evaluation of Mucosal Healing in
In an alternative approach, we previously reported the predictability of MH in UC by a fecal immunochemical test (FIT) ( 12 ) . Quantitative FIT measures fecal hemoglobin concentrations using an antibody specifi c for human hemoglobin, and has been used to screen for colorectal neoplasia ( 13 ) . Th e FIT that we used predicted MH in UC, defi ned as a Mayo endoscopic subscore of 0 (MES 0), with 92% sensitivity and 71% specifi city ( 12 ) . Moreover, FITs have the advantage that the amount of blood can be rapidly measured in many fecal samples in one batch with automated equipment, because the original purpose of FITs was rapid screening for colorectal cancer (CRC) among a large population ( 13 ) . However, it is unknown whether Fcal or FIT predicts MH more accurately in UC patients.
In this study, therefore, we prospectively examined Fcal and conducted a FIT simultaneously using stool samples from UC patients who underwent colonoscopy. Th e ability to predict MH in UC was then compared between the two modalities.
METHODS

Patients
Since 2006, UC patients who regularly attend Okayama University Hospital have been requested to routinely prepare and bring fecal samples at each visit, including the day of colonoscopy, in order to evaluate the amount of fecal occult blood via FIT. In addition, all consecutive UC patients who underwent scheduled colonoscopy between October 2012 and February 2014 were requested to bring another fecal sample for the examination of Fcal. Both fecal samples were collected on the day or a few days before colonoscopy, and stored in a refrigerator until the day of colonoscopy. All of the patients had an established diagnosis of UC according to endoscopic and histologic assessments and had received adequate medical therapy. Mucosal status assessed via colonoscopy was compared with the results of FIT vs. Fcal.
Clinical disease activity was evaluated by using the Mayo score (Scoring Systems for Assessment of UC), consisting of the following four subscores: stool frequency (0, normal number of stools for this patient; 1, 1-2 stools more than normal; 2, 3-4 stools more than normal; and 3, ≥5 stools more than normal), rectal bleeding (0, no blood seen; 1, streaks of blood with stool less than half the time; 2, obvious blood with stool most of the time; and 3, blood alone passed), endoscopic fi ndings (0, normal or inactive disease; 1, mild disease with erythema, decreased vascular pattern, mild friability; 2, moderate disease with marked erythema, absent vascular pattern, friability, erosions; and 3, severe disease with spontaneous bleeding, ulceration), and physician's global assessment (0, normal; 1, mild disease; 2, moderate disease; and 3, severe disease) ( 14 ) . Clinical remission was defi ned as a Mayo stool frequency subscore of 0 or 1 and a Mayo rectal bleeding subscore of 0 ( 15 ) . Patients who failed to fulfi ll the defi nition of clinical remission were considered to have clinically active disease.
FIT analysis
Details of the method used for FIT have been described previously ( 12, 16 ) . In brief, patients collected fecal samples using an OC-Hemodia sampling probe (Eiken Chemical, Tokyo, Japan). Submitted stool samples were immediately processed and examined using OC-SENSOR neo (Eiken Chemical) that can accurately measure fecal hemoglobin concentrations from 50 to 1,000 ng/ml. Fecal specimens with a hemoglobin concentration of >1,000 ng/ml were measured by further dilution, whereas those with a hemoglobin concentration of <50 ng/ml were categorized as one (0-50 ng/ml) because FIT results are inaccurate when the hemoglobin concentration is <50 ng/ml.
Fcal analysis
Fecal samples collected by the patients for calprotectin analysis were stored at −70 °C until shipment to the laboratory. Th e samples were sent to the Institute of Applied Technology for Innate Immunity (Kagawa, Japan), where calprotectin in stools is measured by a Phical Calprotectin enzyme-linked immunosorbent assay (ELISA) kit (Immundiagnostik AG, Benshem, Germany). Th e quantitative range of calprotectin was between 0.65 and 84,000 μ g/g aft er the appropriate dilution of fecal samples ranging from 1:50 to 1:100,000.
Colonoscopy
Bowel preparation was performed with a polyethylene glycolbased or magnesium citrate-based electrolyte solution according to the standard protocol in our hospital. Aft er the colonic lavage fl uid was cleared, patients underwent colonoscopy. Patients were excluded from the study if the colonoscopic examination was incomplete because of problems with the bowel preparation or if the colonoscope could not be inserted into the cecum.
Th e mucosal status of UC patients was assessed via the MES classifi cation. Evaluation was performed at each portion of the colorectum (cecum and ascending colon combined, transverse colon, descending colon, sigmoid colon, and rectum), and the maximum score in the colorectum of each patient was used for analysis. Th e total infl ammation score was defi ned as the sum of MES in the fi ve colonic portions, and ranged from 0 (no infl ammation) to 15 (severe and extensive infl ammation). MH was defi ned as an MES of 0, or 0 or 1 throughout the colorectum. Some patients underwent biopsy from the portion with maximum endoscopic infl ammation for pathological examinations. All colonoscopic examinations were performed by experienced colonoscopists who were blind to the results of the FIT and Fcal.
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In addition, the MES and the fecal results of each patient were determined independently by investigators who did not know patient's status including symptoms.
Pathologic fi ndings
Histologic studies were evaluated using Geboes scores ( 17 ) by gastrointestinal pathologists. Geboes scores for assessment of UC histologic disease activity and MH are classifi ed into 6 grades from grade 0 to grade 5: grade 0 (subgrades 0.0 to 0.3), structural (architectural changes); grade 1 (subgrades 1.0 to 1.3), chronic infl ammatory infi ltrate; grade 2, lamina propria neutrophils and eosinophils (subgrades 2A.0 to 2A.3 for eosinophils, subgrades 2B.0 to 2B.3 for neutrophils); grade 3 (subgrades 3.0 to 3.3), neutrophils in epithelium; grade 4 (subgrades 4.0 to 4.3), crypt destruction; grade 5 (subgrades 5.0 to 5.4), erosion or ulceration. When one or more biopsy specimens were evaluated on each patient, the highest score was used for analysis.
Statistical analysis
Patient characteristics were analyzed by the JMP program (version 11.0 for Windows, SAS Institute, Cary, NC). Sensitivity, specifi city, positive predictive value and negative predictive value with 95% confi dence intervals (CIs) for detecting mucosal status were determined based on the FIT and calprotectin results. To estimate appropriate cutoff values for FIT and calprotectin, receiver operating characteristic (ROC) curve analysis was performed, and the area under the curve was calculated. Spearman's rank correlation test was performed to determine the correlation coeffi cient between the FIT values or Fcallevels and the Mayo endoscopic scores. All P values were two sided and considered statistically signifi cant when <0.05.
Ethical considerations
Th is study was approved by the institutional review board of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences. Informed consent was obtained from each patient before bringing fecal samples.
RESULTS
Clinical characteristics of patients
Th e study included 105 colonoscopies that were accompanied by corresponding FIT and calprotectin results and were performed in 92 UC patients (53 men and 39 women; median age at UC onset, 35.5 years; Table 1 ). Among the 92 UC patients, 63 (69%) had pancolitis, 23 (25%) had left -side colitis, and 6 (6%) had proctitis.
Of the 105 colonoscopy cases, 77 (73%) were performed in patients in clinical remission, whereas the other 28 (27%) were performed in patients with clinically active disease. Colonoscopy fi ndings revealed that the maximum MES for the colorectum was MES 0 in 44 (42%) cases, MES 1 in 20 (19%) cases, MES 2 in 35 (33%) cases, and MES 3 in 6 (6%) cases. Th e distribution of the FIT results showed 56 (53%) cases with a hemoglobin concentration of ≤50 ng/ml, 9 (9%) with 51-100 ng/ml, and 40 (38%) Takashima et al.
with ≥101 ng/ml. On the other hand, the results of Fcal indicated 51 (49%) cases with a concentration of ≤200 μ g/g, 25 (24%) with 201-400 μ g/g, and 29 (27%) with ≥401 μ g/g. Of the total 105 cases, 93 underwent biopsy for pathological examinations. Of these, 4 were excluded because of suspected neoplastic change, and the remaining 89 were evaluated with Geboes score ( Table 2 ) .
Correlations between FIT, Fcal, and colonoscopic fi ndings
Th e correlations between FIT, Fcal, and colonoscopic fi ndings (maximum MES in the colorectum and the total infl ammation score) were analyzed. Both the FIT results and Fcal levels were signifi cantly correlated with both the maximum MES (Spearman's rank correlation coeffi cient: 0.61, P <0.0001 vs. 0.58, P <0.0001) and the total infl ammation score (Spearman's rank correlation We also performed subanalysis using the data of only the fi rst colonoscopy case per patient ( Supplementary Tables S1-S4 online), and subanalysis for patients with pancolitis and for those with left -side colitis, separately ( Supplementary Tables S5-S8 ). Th ese results did not diff er largely from those of the results using all colonoscopy data. Moreover, we confi rmed that fulfi llment of both FIT <100 ng/ml and Fcal <250 μ g/g could raise the specifi city to MES 0 alone up to 0.77 ( Supplementary Table S9 ). All through the analyses, the presence of infl ammatory polyps did not aff ect the results of FIT and Fcal (data not shown).
Th ese results suggest that both FIT and Fcal can predict MH in UC to a similar extent. However, FIT appeared to have an advantage over Fcal with higher sensitivity to predict complete MH (MES 0 alone), although the superiority was not proved because of overlapped CIs. Th e robust predictability regardless of the cutoff value used for prediction seemed to be another merit of FIT.
DISCUSSION
To date, the goal of treatment in UC has been considered to be MH because it reduces the risk of relapse and colectomy ( 1 ) . Although MH may be a good marker in the treatment of UC, a major disadvantage of using MH in clinical practice is its absolute requirement for colonoscopy that is an invasive and costly procedure. Th erefore, coeffi cient: 0.64, P <0.0001 vs. 0.60, P <0.0001; Figures 1 and 2 ). Th us, the correlation coeffi cients of the FIT values to endoscopic scores were slightly higher than those of Fcal values to endoscopic scores. A signifi cant correlation was also observed between the FIT values and Fcal levels (Spearman's rank correlation coefficient: 0.64, P <0.0001; Figure 3 ).
Correlation between FIT, Fcal, colonoscopic fi ndings, and histological fi ndings
Th e correlation between FIT, Fcal, colonoscopic fi ndings, and histological fi ndings in the 89 cases were analyzed. Th e maximum Geboes score was signifi cantly correlated with the maximum MES and the sum of MES (Spearman's rank correlation coefficient: 0.70, P <0.0001, and 0.67, P <0.0001, respectively). In addition, the histological score was also correlated with both FIT and Fcal to a similar extent (Spearman's rank correlation coeffi cient: 0.43, P <0.0001, and 0.43, P <0.0001, respectively).
Sensitivity, specifi city, and predictive value of FIT vs. Fcal for mucosal healing
Th e sensitivity, specifi city, positive predictive value, negative predictive , and accuracy of FIT vs. Fcal data in relation to MH were calculated for the 105 colonoscopy cases. Th e calculation was performed for two defi nitions of mucosal healing: MES 0 alone ( Tables 3 and 4 ), and MES 0 or 1 ( Tables 5 and 6 ). In addition, two types of cutoff values were set for each fecal marker: the cutoff commonly used for CRC screening by FIT (<100 ng/ml) or for MH in infl ammatory bowel disease by Fcal (<250 μ g/g) (standard cutoff s); and the cutoff s optimized by ROC analysis (optimal cutoff s).
When MH was defi ned as MES 0 alone, the sensitivity of FIT was more than 10 points higher than that of Fcal based on either the standard or the optimal (<75 ng/ml for FIT and <200 μ g/g for surrogate markers of mucosal status have been sought and evaluated. Among several candidates, Fcal has become a front runner, particularly in Western countries. Meanwhile, we have reported the utility of FIT in predicting MH in UC ( 12 ); furthermore, this marker is promising because of its growing availability worldwide because it has been replacing the guaiac-based test in the fi eld of CRC screening. Against this background, in this study we compared the ability of Fcal and FIT to predict mucosal healing. Our prospective analysis indicated that Fcal and FIT were equivalent in their ability to predict MH in UC patients. 
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that the prognosis of patients with MES 0 did not diff er from that of patients with MES 1 ( 15, 20, 21 ) , whereas others showed a signifi cant diff erence in prognosis between patients with MES 0 and those with MES 1 ( 2 ). We also observed a signifi cant diff erence in risk of relapse between patients with each defi nition in a previous study ( 22 ) . Although further studies are required to confi rm the diff erence in prognosis between the defi nitions of mucosal healing, the higher sensitivity of FIT as compared with Fcal toward MES 0 alone suggests that FIT might be a more useful marker than Fcal in predicting a reduced risk of relapse. Cost saving is another merit of using FIT in place of Fcal in monitoring UC. Th e cost of one-time FIT is ∼ $22, whereas that of Fcal is $180. Because monitoring with fecal samples has to be performed repeatedly during years of each patient's disease course, the cost-saving eff ect would be extremely large. More importantly, of 28 cases with clinically active disease, 23 (82%) presented positive FIT (>100 ng/ml) with active mucosal features (MES 1 or more). Th erefore, these patients could be regarded as those who require additional treatment without performing colonoscopy, and only the remaining 5 cases with a negative FIT result would have to receive colonoscopy to confi rm the activity of mucosal infl ammation. Th us, the potential of reduction of the cost of colonoscopy by using FIT would also be large.
Notably, measurement of Fcal is performed by ELISA systems, for which there are many assay kits including Phical Calprotectin ELISA kit (used in this study), Calprest ( 10 ), Calprotectine Buhlmann ELISA ( 8, 9 ) , and quantitative point-of-care test ( 8 ) . Previous studies have used diff erent assay kits; therefore, the sensitivity, specifi city, predictive values, as well as cutoff values used for prediction have varied among studies. Moreover, even when the same kit has been used in studies, the cutoff values for prediction have sometimes diff ered. Th us, Fcal has a major drawback in terms of the lack of a standard assay method and standard cutoff values.
In contrast, the FIT system used in this study (OC-sensor, Eiken Chemical) is the system that is most widely used worldwide. Th e FIT cutoff value of 100 ng/ml is the standard value used for CRC screening ( 3, 13 ) . In this study, we analyzed the sensitivity, specifi city, and predictive values of FIT using two cutoff values-the fi xed value of 100 ng/ml and the optimal cutoff calculated by ROC analysis-and large diff erences were not observed between values using either cutoff . In this regard, moreover, the relatively high optimal cutoff to detect MES 0 or 1 of FIT (280 ng/ml) may be attributable to this highly sensitive nature of FIT to slight mucosal infl ammation. Th us, the availability of a standard method and the robust cutoff value are strengths of the FIT. Moreover, the fact that FIT can be measured within a short time (∼ 7 min) with automated equipment is also a strong advantage.
Th ere are several limitations to this study. First, although the study was designed in a prospective manner, the sample size was relatively small, and the number of patients with MES 0 was large. Th e practical utility of FIT vs. Fcal needs to be verifi ed in large studies in the future. Second, the diff erence in the manner of sampling of stools between FIT and Fcal might have aff ected the results. On one hand, the sampling method for FIT was standardized with a specifi c sampling kit including a probe and a tube; thus, the Several reports have indicated that Fcal can predict MH in UC with 65-100% sensitivity and with 53-90% specifi city (8) (9) (10) (11) . In this study, the sensitivity and specifi city of Fcal using optimal cutoff s were 77% and 72%, respectively, for MES 0 alone as mucosal healing. In addition, the values were 86% and 63%, respectively, for MES 0 or 1 as mucosal healing. Th us, the present study data for Fcal are in line with those in previous studies.
On the other hand, there are discrepancies in the sensitivity, specifi city, and optimal cutoff value of the FIT between this and our previous study ( 12 ) . In particular, the sensitivity for predicting MES 0 or 1 was higher in the present study than in the previous report (86% vs. 58%). Th e discrepancy may be attributable to the diff erence in study design (prospective vs. retrospective) and/or to characteristics of the patients (patients with MES 0, 42% vs. 15%). In contrast, the sensitivity for predicting MES 0 is similarly high (93% vs. 94%) between the two studies. Th us, the FIT results of this study are reasonable.
A previous study compared the predictability of mucosal infl ammation between Fcal and fecal hemoglobin ( 18 ) . In contrast to the present study, the report examined fecal hemoglobin concentrations by using an ELISA system. Th e study revealed that the sensitivity and specifi city of fecal hemoglobin toward the presence of mucosal infl ammation were equivalent to those of Fcal. In clinical practice, however, the prediction of MH is more relevant than the prediction of mucosal infl ammation, because UC patients with mucosal infl ammation are likely to have symptoms, but asymptomatic UC patients do not always show mucosal healing. Moreover, MH has been considered to be the treatment goal because it reduces the risk of relapse. To our knowledge, this is the fi rst report to compare the predictability of MH by Fcal and FIT. Our results indicate that FIT can replace Fcal with regard to the prediction of mucosal healing, particularly the prediction of MES 0 alone. As the automated FIT analyzer grows in availability owing to its use in CRC screening, FIT may become more common in infl ammatory bowel disease practice.
As compared with Fcal, FIT was found to be a better predictor of more strictly defi ned MH (MES 0 alone) in this study. Until now, the defi nition of MH has not been established. Older reports were likely to defi ne MH as MES 0 or 1 ( 15, (19) (20) (21) , whereas more recent studies have defi ned MH as MES 0 alone ( 2, 22, 23 ) . MH should be determined in correlation with prognosis including risk of relapse and colectomy. In this context, some studies reported variation in results because of sampling is expected to be relatively small. On the other hand, there are no standardized collection kits for Fcal. Th e lack of the standardized kits may have yielded the difference in the way of collecting stools among patients and aff ected the results of Fcal. In this regard, the potentially small variation caused by sampling may be considered to be a further advantage of FIT. Th ird, the results of FIT may have been aff ected by the presence of hemorrhoid. In this regard, however, previous reports regarding CRC screening indicated that the presence of hemorrhoid did not signifi cantly aff ect the results of FIT ( 24, 25 ) .
In conclusion, our study revealed that both FIT and Fcal eff ectively predicted MH in UC patients. Th e results also indicated that FIT is more sensitive toward MES 0 than Fcal. Th e diff erence in clinical utility, including predictability for risk of relapse or colectomy, between the two fecal tests should be further investigated.
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